CONMED Corporation CNMD
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About CNMD
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
CONMED Corporation is a U.S.-based medical technology company that develops, manufactures, and sells surgical devices and equipment used primarily in minimally invasive procedures and orthopedic surgery. The company operates within the broader medical devices and healthcare technology industries, with products used by hospitals, ambulatory surgery centers, and healthcare providers globally. CONMED’s principal revenue drivers include surgical instruments, arthroscopy products, electrosurgery systems, endoscopic technologies, and advanced visualization platforms used across orthopedic, gastroenterology, pulmonology, and general surgery applications.
The company’s operations are primarily organized around two major business categories: Orthopedics and General Surgery. CONMED has positioned itself as a specialist in minimally invasive surgical technologies, particularly in arthroscopy and powered surgical instruments. Its strategic positioning is supported by long-standing relationships with surgeons, a broad disposable-product portfolio that generates recurring revenue, and integrated procedural solutions designed to improve operating room efficiency. Founded in 1970 by Eugene Corasanti, CONMED evolved from a regional medical device supplier into a globally diversified surgical technology company through internal product development and acquisitions, including the acquisition of Buffalo Filter and Linvatec.
Business Operations
CONMED generates revenue through the sale of capital equipment, single-use consumables, implants, and surgical accessories. Its Orthopedics business includes arthroscopy implants, powered surgical instruments, visualization systems, and biologic products used in sports medicine and orthopedic procedures. The General Surgery segment includes electrosurgery products, smoke evacuation systems, endoscopic technologies, insufflation equipment, and advanced energy devices used in laparoscopic and gastrointestinal procedures. A significant portion of revenue is derived from disposable products that are repeatedly used in surgical procedures, supporting recurring sales.
The company operates across domestic and international markets, with sales infrastructure spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East. CONMED controls manufacturing, research and development, and distribution capabilities across multiple facilities globally. Key subsidiaries and acquired businesses include Linvatec, which strengthened the company’s orthopedic surgery portfolio, and Buffalo Filter, which expanded its surgical smoke evacuation capabilities. CONMED also maintains partnerships with healthcare providers and distributors to support international market penetration and product adoption.
Strategic Position & Investments
CONMED’s strategic direction has focused on expanding its minimally invasive surgery portfolio, increasing recurring revenue from disposable products, and growing internationally. The company has invested in surgeon education, product innovation, and procedural workflow integration to strengthen its competitive position in orthopedic and general surgery markets. Growth initiatives have included expansion in ambulatory surgery centers, continued development of arthroscopy technologies, and broader adoption of advanced surgical visualization systems.
The company has also pursued targeted acquisitions to strengthen product breadth and procedural specialization. The acquisition of In2Bones Global, Inc. expanded CONMED’s presence in extremities and small bone orthopedic procedures, while earlier acquisitions such as Buffalo Filter enhanced its leadership in surgical smoke evacuation technologies. CONMED has invested in emerging areas such as advanced minimally invasive surgical tools, wireless visualization technologies, and integrated operating room systems intended to improve surgical efficiency and patient outcomes. Public filings and investor communications indicate continued emphasis on innovation-led growth and international expansion.
Geographic Footprint
CONMED is headquartered in Largo, Florida, with operational and commercial activities extending across multiple continents. The company maintains a substantial presence in the United States, which remains its largest market, while also operating throughout Europe, Asia-Pacific, Latin America, Canada, and portions of the Middle East. International sales contribute a meaningful share of total revenue, supported by both direct sales teams and third-party distribution networks.
The company’s manufacturing, research, and distribution infrastructure supports global healthcare systems and surgical providers in developed and emerging markets. CONMED has strategically expanded its international footprint through localized commercial operations and product registrations tailored to regional regulatory requirements. Its global operational reach enables participation in both hospital-based and outpatient surgical procedure growth trends worldwide.
Leadership & Governance
CONMED is governed by a board of directors and executive leadership team focused on operational execution, innovation, and shareholder value creation. The company’s leadership strategy emphasizes disciplined capital allocation, procedural innovation, and long-term growth within minimally invasive surgery markets. Public company disclosures, including SEC filings, indicate a governance structure aligned with standard U.S. public company practices, including independent board oversight and executive accountability measures.
Key executives include:
- Patrick J. Beyer – President and Chief Executive Officer
- Luke A. Pomilio – Executive Vice President and Chief Financial Officer
- Martha Goldberg Aronson – Chair of the Board
- Todd Garner – Executive Vice President and President, Orthopedics
- Patrice McKinney – Executive Vice President and Chief Human Resources Officer
Leadership communications and investor materials emphasize operational excellence, surgeon-focused product innovation, international growth, and expansion of recurring revenue streams through disposable surgical products and procedural solutions.